Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases

被引：6
|
作者：
Sengler, C. [1 ]
Niewerth, M. [1 ]
Kallinich, T. [2 ]
Nimtz-Talaska, A.
Haller, M.
Huppertz, H. -I. [3 ]
Minden, K. [1 ]
机构：
[1] German Rheumatism Res Ctr Berlin, Leibniz Inst, Epidemiol Unit, D-10117 Berlin, Germany
[2] Charite, Childrens Univ Hosp, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany
[3] Klinikum Bremen Mitte, Bremen, Germany
来源：
CLINICAL RHEUMATOLOGY | 2014年 / 33卷 / 01期
关键词：
Children; Disease activity; Flare; H1N1 influenza vaccination; Rheumatic disease; JUVENILE IDIOPATHIC ARTHRITIS; SAFETY; IMMUNOGENICITY;
D O I：
10.1007/s10067-013-2435-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented-38 % under treatment with biologicals-of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.
引用
收藏
页码：137 / 139
页数：3
相关论文
共 50 条
  • [1] Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases
    C. Sengler
    M. Niewerth
    T. Kallinich
    A. Nimtz-Talaska
    M. Haller
    H.-I. Huppertz
    K. Minden
    Clinical Rheumatology, 2014, 33 : 137 - 139
  • [2] Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza
    Ortqvist, Ake
    Bennet, Rutger
    Rinder, Malin Ryd
    Lindblad, Hans
    Eriksson, Margareta
    VACCINE, 2012, 30 (39) : 5699 - 5702
  • [3] Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine
    Javelle, Emilie
    Soulier, Benjamin
    Brosset, Christian
    Lorcy, Solene
    Simon, Fabrice
    VACCINE, 2011, 29 (06) : 1123 - 1125
  • [4] Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial
    Nolan, Terry
    Roy-Ghanta, Sumita
    Montellano, May
    Weckx, Lily
    Ulloa-Gutierrez, Rolando
    Lazcano-Ponce, Eduardo
    Kerdpanich, Angkool
    Palazzi Safadi, Marco Aurelio
    Cruz-Valdez, Aurelio
    Litao, Sandra
    Lim, Fong Seng
    Mascarenas de Los Santos, Abiel
    Rodriguez Weber, Miguel Angel
    Tinoco, Juan-Carlos
    Hernandez-de Mezerville, Marcela
    Faingezicht, Idis
    Kosuwon, Pensri
    Lopez, Pio
    Borja-Tabora, Charissa
    Li, Ping
    Durviaux, Serge
    Fries, Louis
    Dubin, Gary
    Breuer, Thomas
    Innis, Bruce L.
    Vaughn, David W.
    JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (04) : 545 - 557
  • [5] Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients
    Manuel, Oriol
    Pascual, Manuel
    Hoschler, Katja
    Giulieri, Stefano
    Alves, Deolinda
    Ellefsen, Kim
    Bart, Pierre-Alexandre
    Venetz, Jean-Pierre
    Calandra, Thierry
    Cavassini, Matthias
    CLINICAL INFECTIOUS DISEASES, 2011, 52 (02) : 248 - 256
  • [6] Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine
    Walker, Woolf T.
    Faust, Saul N.
    EXPERT REVIEW OF VACCINES, 2010, 9 (12) : 1385 - 1398
  • [7] Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months
    Carmona, Alfonso
    Omenaca, Felix
    Tejedor, Juan C.
    Merino, Jose M.
    Vaman, Tejaswini
    Dieussaert, Ilse
    Gillard, Paul
    Aristegui, Javier
    VACCINE, 2010, 28 (36) : 5837 - 5844
  • [8] Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials
    Launay, Odile
    Duval, Xavier
    Fitoussi, Serge
    Jilg, Wolfgang
    Kerdpanich, Angkool
    Montellano, May
    Schwarz, Tino F.
    Watanveerade, Veerachai
    Wenzel, Jurgen J.
    Zalcman, Gerard
    Bambure, Vinod
    Li, Ping
    Caplanusi, Adrian
    Madan, Anuradha
    Gillard, Paul
    Vaughn, David W.
    BMC INFECTIOUS DISEASES, 2013, 13
  • [9] A Prospective Study of the Factors Shaping Antibody Responses to the AS03-Adjuvanted Influenza A/H1N1 Vaccine in Cancer Outpatients
    Hottinger, Andreas F.
    George, Anne-Claude C.
    Bel, Michael
    Favet, Laurence
    Combescure, Christophe
    Meier, Sara
    Grillet, Stephane
    Posfay-Barbe, Klara
    Kaiser, Laurent
    Siegrist, Claire-Anne
    Dietrich, Pierre-Yves
    ONCOLOGIST, 2012, 17 (03) : 436 - 445
  • [10] HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children
    Leahy, Timothy R.
    Goode, Michelle
    Lynam, Paul
    Gavin, Patrick J.
    Butler, Karina M.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2014, 8 (03) : 360 - 366
12345